Pay in 4 interest-free payments of $5.55 Learn more
Ships within 48 hours · Estimated delivery Aug 1 - Aug 6
Appetite suppression through dopamine modulation Central appetite control: Tesofensine acts on hypothalamus Affects arcuate nucleus (appetite center) Different pathway from GLP-1 receptors Direct neurotransmitter modulation Rapid onset (hours not days) Dopamine's role in eating: Mediates food reward (hedonic eating) High-dopamine = reduced food seeking Decreases obsessive food thoughts Reduces binge eating tendencies Similar to ADHD medication effects Subjective appetite changes reported: Reduced hunger (moderate, not as strong as semaglutide ) Less food preoccupation Earlier satiety (smaller portions satisfying) Reduced cravings especially for high-calorie foods More mental focus on non-food activities Appetite suppression comparison: Why dopamine approach different: Addresses psychological/behavioral eating Reduces food as reward behavior Helps with emotional eating Less GI side effects than GLP-1s But creates stimulant-like dependency risk Clinical trial results and efficacy Evidence from human studies
Grocott, Editor-in-Chief, Canadian Journal of Anesthesia
It is not for human or veterinary use under any circumstances
By potentially downregulating TGF-1, AHK-Cu may alter these cellular processes, possibly affecting cell growth and the immune response at a cellular level
US$ 29.45
US$ 21.03
US$ 23.57
